Sarcolemmal KATP channel modulators and cardiac arrhythmias

Current Medicinal Chemistry

Volumn 18, Issue 24, 2011, Pages 3640-3661

  Baczko I ^a   Husti, Z ^a   Lang, V ^b   Lepran I ^a   Light, P E ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ATP sensitive potassium channel; Atrial fibrillation; Cardiac arrhythmias; KATP channel blockers; Mitochondrial KATP channel; Potassium channel openers; Repolarization; Reverse use dependent prolongation of repolarization; Sarcolemmal KATP channel

Indexed keywords

2 CYANO 1 (1 ISOPROPYLPROPYL) 3 (4 PYRIDYL)GUANIDINE; 2 CYANO 1 (1,1 DIMETHYLPROPYL) 3 (3 PYRIDYL)GUANIDINE; 5 HYDROXYDECANOIC ACID; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; APRIKALIM; BMS 191095; CARBUTAMIDE; CLAMIKALANT; CROMAKALIM; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HMR 1402; KR 31761; KR 31762; LEMAKALIM; MINOXIDIL; MINOXIDIL SULFATE; N (4 CHLOROPHENYL) N' CYANO N'' (6 CYANO 3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 2H 1 BENZOPYRAN 4 YL)GUANIDINE; NICORANDIL; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; SULFONYLUREA; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ISOPROTEIN; POTASSIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; ADVERSE OUTCOME; ARRHYTHMOGENESIS; ARTICLE; CARDIOSELECTIVITY; CELL METABOLISM; CLINICAL TRIAL; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART MITOCHONDRION; HEART MUSCLE EXCITABILITY; HEART MUSCLE FIBER MEMBRANE; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC STRESS; MORTALITY; NONHUMAN; PURKINJE FIBER; REPERFUSION INJURY; STROKE; SUDDEN DEATH; TISSUE DISTRIBUTION; TORSADE DES POINTES; ANIMAL; DRUG ANTAGONISM; GENETICS; METABOLISM; PATHOLOGY; REVIEW; SARCOLEMMA;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; HUMANS; KATP CHANNELS; POTASSIUM CHANNEL BLOCKERS; PROTEIN ISOFORMS; SARCOLEMMA;

EID: 80052004018     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796642472     Document Type: Article

References (276)

1. Bayés de Luna, A.; Coumel, P.; Leclercq, J.F. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am. Heart J., 1989, 117, 151-159. (Pubitemid 19043766)
2. Zipes, D.P.; Wellens, H.J. Sudden cardiac death. Circulation, 1998, 98, 2334-2351. (Pubitemid 28533855)
3. Fishman, G.I.; Chugh, S.S.; Dimarco, J.P.; Albert, C.M.; Anderson, M.E.; Bonow, R.O.; Buxton, A.E.; Chen, P.S.; Estes, M.; Jouven, X.; Kwong, R.; Lathrop, D.A.; Mascette, A.M.; Nerbonne, J.M.; O'Rourke, B.; Page, R.L; Roden, D.M.; Rosenbaum, D.S.; Sotoodehnia, N.; Trayanova, N.A.; Zheng, Z.J. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation, 2010, 122, 2335-2348.
4. Zheng, Z.J.; Croft, J.B.; Giles, W.H.; Mensah, GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation, 2001, 104, 2158-2163. (Pubitemid 33043293)
5. Huikuri, H.V.; Castellanos, A.; Myerburg, R.J. Sudden death due to cardiac arrhythmias. N Engl J Med., 2001, 345, 1473-1482.
6. Kjekshus, J. Arrhythmias and mortality in congestive heart failure. Am. J. Cardiol., 1990, 65, 421-481.
7. Guerra, P.G.; Talajic, M.; Roy, D.; Dubuc, M.; Thibault, B.; Nattel, S. Is there a future for antiarrhythmic drug therapy? Drugs, 1998; 56, 767-781. (Pubitemid 28525937)
8. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after after myocardial infarction. N. Engl. J. Med., 1989, 321, 406-412.
9. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N. Engl. J. Med., 1992, 327, 227-233.
10. Mason, J.W. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N. Engl. J. Med., 1993, 329, 452-458. (Pubitemid 23222330)
11. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest. (The CASCADE Study). Am. J. Cardiol., 1993, 72, 280-287.
12. Waldo, A.L.; Camm, A.J.; deRuyter, H.; Friedman, P.L.; MacNeil, D.J.; Pauls, J.F.; Pitt, B.; Pratt, C.M.; Schwartz, P.J.; Veltri, E.P. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral D-sotalol. Lancet, 1996, 348, 7-12. (Pubitemid 26237238)
13. Hohnloser, S.H.; Singh, B.N. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J. Cardiovasc. Electrophysiol., 1995, 6, 920-936.
14. Kannel, W.B.; Abbott, R.D.; Savage, D.D.; McNamara, P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N. Engl. J. Med., 1982, 306, 1018-1022. (Pubitemid 12155370)
15. Benjamin, E.J.; Wolf, P.A.; D'Agostino, R.B.; Silbershatz, H.; Kannel, W.B.; Levy, D. Impact of atrial fibrillation on the risk of death. The Framingham heart study. Circulation, 1998, 98, 946-952. (Pubitemid 28446646)
16. Naccarelli, G.V.; Varker, H.; Lin, J.; Schulman, K.L. Increasing Prevalence of Atrial Fibrillation and Flutter in the United States. Am. J. Cardiol., 2009, 104, 1534-1539.
17. Lloyd-Jones, D.M.; Wang, T.J.; Leip, E.P.; Larson, M.G.; Levy, D.; Vasan, R.S.; D'Agostino, R.B.; Massaro, J.M.; Beiser, A.; Wolf, P.A.; Benjamin, E.J. Lifetime risk for development of atrial fibrillation. The Framingham Heart Study. Circulation, 2004, 110, 1042-1046.
18. Heeringa, J.; van der Kuip, D.A.; Hofman, A.; Kors, J.A.; van Herpen, G.; Stricker, B.H.; Stijnen, T.; Lip, G.Y.; Witteman, J.C. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J., 2006, 27, 949-953.
19. Bajpai, A.; Savelieva, I.; Camm, A.J. Treatment of atrial fibrillation. B r. Med. Bull., 2008, 88, 75-94.
20. Ehrlich, J.R.; Biliczki, P.; Hohnloser, S.H.; Nattel, S. Atrial-selective approaches for the treatment of atrial fibrillation. J. Am. Coll. Cardiol., 2008, 51, 787-792. (Pubitemid 351253743)
21. ATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat. Clin. Pract. Cardiovasc. Med., 2007, 4, 110-116. (Pubitemid 46165273)
22. ATP: atrial K(ATP) channels require SUR1. Circ. Res., 2008, 103, 1458-1465.
23. Fukuzaki, K.; Sato, T.; Miki, T.; Seino, S.; Nakaya, H. Role of sarcolemmal ATP-sensitive K+ channels in the regulation of sinoatrial node automaticity: an evaluation using Kir6.2-deficient mice. J. Physiol, 2008, 586, 2767-2778. (Pubitemid 351766597)
24. + channels in cardiac muscle. Nature, 1983, 305, 147-148. (Pubitemid 14235671)
25. Deutsch, N; Klitzner, T.S.; Lamp, S.T.; Weiss, J.N. Activation of cardiac ATP-sensitive K+ current during hypoxia: correlation with tissue ATP levels. Am. J. Physiol, 1991, 261, H671-H676.
26. Cole, W.C.; McPherson, CD.; Sontag, D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ. Res., 1991, 69, 571-581.
27. McPherson, CD.; Pierce, G.N.; Cole, W.C. Ischemic cardioprotection by ATPsensitive K+ channels involves high-energy phosphate preservation. Am. J. Physiol, 1993, 265, H1809-H1818. (Pubitemid 23348218)
28. Hearse, D.J. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc. Res., 1995, 30, 1-17.
29. Light, P.E.; Kanji, H.D.; Fox, J.E.; French, R.J. Distinct myoprotective roles of cardiac sarcolemmal and mitochondrial KATP channels during metabolic inhibition and recovery. FASEB J., 2001; 15, 2586-2594. (Pubitemid 33131085)
30. Parratt, J.R. Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci, 1994, 15, 19-25. (Pubitemid 24027446)
31. Cohen, M.V.; Downey, J.M. Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. Annu. Rev. Med, 1996, 47, 21-29.
32. Wolleben, CD.; Sanquinetti, M.C.; Siegl, P.K.S. Influence of ATP-sensitive potassium modulators on ischemia-induced fibrillation in isolated rat hearts. J. Mol Cell Cardiol, 1989, 21, 783-788. (Pubitemid 19225946)
33. Chi, L.; Uprichard, A.C.; Lucchesi, B.R.; Profibrillatory actions of pinacidil in a conscious canine model of sudden coronary death. J. Cardiovasc. Pharmacol, 1990, 15, 452-464. (Pubitemid 20063747)
34. D'Alonzo, A.J.; Zhu, J.L.; Darbenzio, R.B.; Dorso, CR.; Grover, G.J. Proarrhythmic effects of pinacidil are partially mediated through enhancement of catecholamine release in isolated perfused guinea-pig hearts. J. Mol Cell Cardiol, 1998, 30, 415-423. (Pubitemid 28116321)
35. Spinelli, W.; Sorota, S.; Siegal, M.; Hoffman, B.F. Antiarrhythmic actions of the ATP-regulated K+ current activated by pinacidil. Circ. Res., 1991, 68, 1127-1137.
36. Carlsson, L.; Abrahamsson, C; Drews, L.; Duker, G. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation, 1992, 85, 1491-1500.
37. Leprán, I.; Baczkó, I.; Varró, A.; Papp, J. Gy. ATP-sensitive potassium channel modulators: both pinacidil and glibenclamide produce antiarrhythmic activity during acute myocardial infarction in conscious rats. J. Pharmacol Exp. Ther, 1996, 277, 1215-1220.
38. Baczkó, I; Leprán, I; Papp, J. Gy. K(ATP) channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats. Eur. J. Pharmacol, 1997, 324, 77-83. (Pubitemid 27160911)
39. Billman, G.E.; Avendano, CE.; Halliwill, J.R.; Burroughs, J.M. The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs. J. Cardiovasc. Pharmacol, 1993, 21, 197-204. (Pubitemid 23027594)
40. Billman, G.E.; Englert, H.C.; Schoelkens, B.A. HMR 1883, a novel cardioselective inhibitor of the ATP- sensitive potassium channel; Part II: effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs. J. Pharmacol Exp. Ther, 1998, 286, 1465-1473. (Pubitemid 29135563)
41. Wirth, K.J.; Rosenstein, B.; Uhde, J.; Englert, H.C.; Busch, A.E.; Schölkens, B.A. ATP-sensitive potassium channel blocker HMR 1883 reduces mortality and ischemia-associated electrocardiographic changes in pigs with coronary occlusion. J. Pharmacol Exp. Ther, 1999, 291, 474-481. (Pubitemid 29503514)
42. Wirth, K.J.; Klaus, E.; Englert, H.G.; Schölkens, B.A.; Linz, W. HMR 1883, a cardioselective K(ATP) channel blocker, inhibits ischaemia- and reperfusion-induced ventricular fibrillation in rats. Naunyn Schmiedebergs Arch. Pharmacol, 1999, 360, 295-300. (Pubitemid 29480920)
43. El-Reyani, N.E.; Bozdogan, Ö.; Baczkó, I.; Leprán, I.; Papp, J. Gy. Comparison of the efficacy of glibenclamide and glimepiride in reperfusion induced arrhythmias in rats. Eur. J. Pharmacol, 1999, 365, 187-192. (Pubitemid 29070764)
44. Billman, G.E.; Houle, M.S.; Englert, H.C.; Gögelein, H. Effects of a novel cardioselective ATP-sensitive potassium channel antagonist 1-[[5-[2(5-chloro-o-anisamido) ethyl]-β-methoxyethoxyphenyl]sulfonyl]-3- methylthioura, sodium salt (HMR 1402), on susceptibility to ventricular fibrillation induced by myocardial ischemia: in vitro and in vivo studies. J. Pharmacol Exp. Ther, 2004, 309, 182-192. (Pubitemid 38393129)
45. Vajda, Sz.; Baczkó, I.; Leprán, I. Selective cardiac plasma-membrane K(ATP) channel inhibition is defibrillatory and improves survival during acute myocardial infarction and ischemia and reperfusion. Eur. J. Pharmacol, 2007, 577, 115-123. (Pubitemid 47632518)
46. Cacciapuoti, F.; Spiezia, R.; Bianchi, U.; Lama, D.; D'Avino, M.; Varricchio, M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am. J. Cardiol, 1991, 67, 843-847.
47. Lomuscio, A.; Vergani, D.; Marano, L.; Castagnone, M.; Fiorentini, C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron. Artery Dis., 1994, 5, 767-771. (Pubitemid 24338677)
48. Billman, G.E. The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy. Pharmacol. Ther., 2008, 120, 54-70.
49. del Valle, H.F.; Lascano, E.C.; Negroni, J.A.; Crottogini, A.J. Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep. Cardiovasc. Res., 2001, 50, 474-485. (Pubitemid 32480241)
50. Ferdinandy, P.; Szilvássy, Z.; Droy-Lefaix, M.T.; Tarrade, T.; Koltai, M. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide. Cardiovasc. Res., 1995, 30, 781-787.
51. Nichols, C.G.; Lederer, W.J. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am. J. Physiol., 1991, 261, H1675-H1686.
52. Aguilar-Bryan, L.; Nichols, C.G.; Wechsler, S.W.; Clement, J.P.4th.; Boyd, A.E.3rd.; González, G.; Herrera-Sosa, H.; Nguy, K.; Bryan, J.; Nelson, D.A. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science, 1995, 268, 423-426.
53. Inagaki, N.; Gonoi, T.; Clement, J.P.; Namba, N.; Inazawa, J.; Gonzalez, G.; Aguilar-Bryan, L.; Seino, S.; Bryan, J. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science, 1995, 270: 1166-1170.
54. Hambrock, A.; Preisig-Müller, R.; Russ, U.; Piehl, A.; Hanley, P.J.; Ray, J.; Daut, J.; Quast, U.; Derst, C. Four novel splice variants of sulfonylurea receptor 1. Am. J. Physiol., 2002, 283, C587-C598. (Pubitemid 34787542)
55. + channels. Neuron, 1996, 16, 1011-1017. (Pubitemid 26171205)
56. Chutkow, W.A.; Simon, M.C.; Le Beau, M.M.; Burant, C.F. Cloning, tissue expression, and chromosomal localization of SUR2, the putative drugbinding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes., 1996, 45, 1439-1445. (Pubitemid 26332911)
57. Nelson, M.T.; Quayle, J.M. Physiological roles and properties of potassium channels in arterial smooth muscle. Am. J. Physiol., 1995, 268, C799-C822.
58. Inoue, I.; Nagase, H.; Kishi, K.; Higuti, T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature, 1991, 352, 244-247. (Pubitemid 21912326)
59. Paucek, P.; Mironova, G.; Mahdi, F.; Beavis, A.D.; Woldegiorgis, G.; Garlid, K.D. Reconstitution and partial purification of the glibenclamide- sensitive, ATP-dependent K+ channel from rat liver and beef heart mitochondria. J. Biol. Chem., 1992, 267, 26062-26069. (Pubitemid 23014017)
60. Garlid, K.D.; Paucek, P.; Yarov-Yarovoy, V.; Murray, H.N.; Darbenzio, R.B.; D'Alonzo, A.J.; Lodge, N.J.; Smith, M.A.; Grover, G.J. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ. Res., 1997, 81, 1072-1082. (Pubitemid 27514958)
61. Liu, Y.G.; Sato, T.; O'Rourke, B.; Marbán, E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation, 1998, 97, 2463-2469. (Pubitemid 28278191)
62. + channels and their role in cardioprotection. Circ. Res., 2004, 94, 420-432. (Pubitemid 38326277)
63. Liu, Y.; Ren, G.; O'Rourke, B.; Marban, E.; Seharaseyon, J. Pharmacological comparison of native mitochondrial KATP channels with molecularly defined surface KATP channels. Mol. Pharmacol., 2001, 59, 225-230. (Pubitemid 32108554)
64. Gaborit, N.; Le Bouter, S.; Szuts, V.; Varro, A.; Escande, D.; Nattel, S.; Demolombe, S. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J. Physiol., 2007, 582, 675-693. (Pubitemid 47040552)
65. Pountney, D.J.; Sun, Z.Q.; Porter, L.M.; Nitabach, M.N.; Nakamura, T.Y.; Holmes, D.; Rosner, E.; Kaneko, M.; Manaris, T.; Holmes, T.C.; Coetzee, W.A. Is the molecular composition of K(ATP) channels more complex than originally thought? J. Mol. Cell. Cardiol., 2001, 33, 1541-1546. (Pubitemid 32681671)
66. Tricarico, D.; Mele, A.; Lundquist, A.L.; Desai, R.R.; George, A.L. Jr.; Conte Camerino, D. Hybrid assemblies of ATP-sensitive K+ channels determine their muscle-type-dependent biophysical and pharmacological properties. Proc. Natl. Acad. Sci. U S A., 2006, 103, 1118-1123. (Pubitemid 43212231)
67. Babenko, A.P.; Gonzalez, G.; Aguilar-Bryan, L.; Bryan, J. Reconstituted human cardiac KATP channels: functional identity with the native channels from the sarcolemma of human ventricular cells. Circ. Res., 1998, 83, 1132-1143. (Pubitemid 28533522)
68. Baron, A.; van Bever, L.; Monnier, D.; Roatti, A.; Baertschi, A.J. A novel K(ATP) current in cultured neonatal rat atrial appendage cardiomyocytes. Circ. Res., 1999, 85, 707-715. (Pubitemid 29480811)
69. Light, P.E.; Cordeiro, J.M.; French, R.J. Identification and properties of ATP-sensitive potassium channels in myocytes from rabbit Purkinje fibres. Cardiovasc. Res., 1999, 44, 356-369. (Pubitemid 29475239)
70. Kantor, P.F.; Coetzee, W.A.; Carmeliet, E.E.; Dennis, S.C.; Opie, L.H. Reduction of ischemic K+ loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulphonylurea. Circ. Res., 1990, 66, 478-485. (Pubitemid 20041178)
71. Zhang, H.L.; Li, Y.S.; Fu, S.X.; Yang, X.P. Effects of glibenclamide and tolbutamide on ischaemia-induced and ouabain-induced arrhythmias and membrane potentials of ventricular myocardium from rat and guinea pig. Acta Pharmacol. Sin., 1991, 12, 398-402.
72. Tosaki, A.; Szerdahelyi, P.; Engelman, R.M.; Das, D.K. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? J. Pharmacol. Exp. Ther., 1993, 267, 1355-1362. (Pubitemid 24068707)
73. D'Alonzo, A.J.; Darbenzio, R.B.; Hess, T.A.; Sewter, J.C.; Sleph, P.G.; Grover, G.J. Effects of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia. Cardiovasc. Res., 1994, 28, 881-887.
74. Dhein, S.; Pejman, P.; Krusemann, K. Effects of the I(KATP) blockers glibenclamide and HMR1883 on cardiac electrophysiology during ischemia and reperfusion. Eur. J. Pharmacol, 2000, 398, 273-84. (Pubitemid 30333355)
75. Gonca, E.; Bozdogan, O. Both mitochondrial K(ATP) channel opening and sarcolemmal K(ATP) channel blockage confer protection against ischemia/reperfusion-induced arrhythmia in anesthetized male rats. J. Cardiovasc. Pharmacol. Ther, 2010, 15, 403-411.
76. Davis, T.M.; Parsons, R.W.; Broadhurst, R.J.; Hobbs, M.S.; Jamrozik, K. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care, 1998, 21, 637-640.
77. Friedel, H.A.; Brogden, R.N. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs, 1990, 39, 929-967.
78. Remme, C.A.; Wilde, A.A. K(ATP) channel openers, myocardial ischemia, and arrhythmias - should the electrophysiologist worry? Cardiovasc. Drugs Ther, 2000, 14, 17-22. (Pubitemid 30139217)
79. Ueda, H.; Nakayama, Y.; Tsumura, K.; Yoshimaru, K.; Hayashi, T.; Yoshikawa, J. Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction. Can. J. Cardiol, 2004, 20, 625-629. (Pubitemid 38811581)
80. Ueda, H.; Hayashi, T.; Tsumura, K.; Yoshimaru, K.; Nakayama, Y; Yoshikawa, J. Intravenous nicorandil can reduce QT dispersion and prevent bradyarrhythmia during percutaneous transluminal coronary angioplasty of the right coronary artery. J. Cardiovasc. Pharmacol. Ther, 2004, 9, 179-184. (Pubitemid 39331064)
81. Végh, A.; György, K.; Papp, J.G.; Sakai, K.; Parratt, J.R. Nicorandil suppressed ventricular arrhythmias in a canine model of myocardial ischaemia. Eur. J. Pharmacol, 1996, 305, 163-168. (Pubitemid 26195991)
82. Gasser, R.N.A.; Vaughan-Jones, R.D. Mechanism of potassium efflux and action potential shortening during ischaemia in isolated mammalian cardiac muscle. J. Physiol, 1990, 431, 713-741.
83. Escande, D.; Cavero, I. K+ channel openers and 'natural' cardioprotection. Trends Pharmacol. Sci., 1992, 13, 269-272.
84. Yao, Z.; Gross, G.J. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation, 1994, 89, 1768-1775.
85. Grover, G.J.; DAlonzo, A.J.; Hess, T.; Sleph, P.G.; Darbenzio, R.B. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening. Cardiovasc Res., 1995, 30, 731-738.
86. Gross, G.J.; Fryer, R.M. Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ. Res., 1999, 84, 973-979. (Pubitemid 29227676)
87. Murry, C.E.; Jennings, R.B.; Reimer, K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 1986, 74, 1124-1136. (Pubitemid 17174962)
88. Végh, A.; Parratt, J.R. The role of mitochondrial K(ATP) channels in antiarrhythmic effects of ischaemic preconditioning in dogs. Br. J. Pharmacol, 2002, 137, 1107-1115. (Pubitemid 35440752)
89. D'hahan, N; Moreau, C; Prost, A.L.; Jacquet, H.; Alekseev, A.E.; Terzic, A.; Vivaudou, M. Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP Proc. Natl. Acad. Sci. USA, 1999, 96, 12162-12167. (Pubitemid 29502875)
90. Grimmsmann, T.; Rustenbeck, I. Direct effects of diazoxide on mitochondria in pancreatic β-cells and on isolated liver mitochondria. Br. J. Pharmacol., 1998, 123, 781-788. (Pubitemid 28085376)
91. Hanley, P.J.; Mickel, M.; Loffler, M.; Brandt, U.; Daut, J. KATP channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart. J. Physiol, 2002; 542, 735-741. (Pubitemid 34947269)
92. Dröse, S.; Brandt, U.; Hanley PJ. K(+)-independent actions of diazoxide question the role of inner membrane K(ATP) channels in mitochondrial cytoprotective signaling. J Biol Chem., 2006, 281, 23733-23739. (Pubitemid 44274148)
93. Lawrence, C.L.; Billups, B.; Rodrigo, G.C.; Standen, N.B. The K(ATP) channel opener diazoxide protects cardiac myocytes during metabolic inhibition without causing mitochondrial depolarization or flavoprotein oxidation. Br. J. Pharmacol, 2001, 134, 535-542. (Pubitemid 32977898)
94. Hanley, P.J.; Gopalan, K.V.; Lareau, R.A.; Srivastava, D.K.; von Meltzer, M.; Daut, J. Beta-oxidation of 5-hydroxydecanoate, a putative blocker of mitochondrial ATP-sensitive potassium channels. J. Physiol, 2003; 547, 387-393. (Pubitemid 36304972)
95. Hanley, P.J.; Drose, S.; Brandt, U.; Lareau, R.A.; Banerjee, A.L.; Srivastava, D.K.; Banaszak, L.J.; Barycki, J.J.; Van Veldhoven, P.P.; Daut, J. 5-hydroxydecanoate is metabolised in mitochondria and creates a rate-limiting bottleneck for -oxidation of fatty acids. J. Physiol, 2005, 562, 307-318.
96. Suzuki, M.; Sasaki, N.; Miki, T.; Sakamoto, N; Ohmoto-Sekine, Y; Tamagawa, M.; Seino, S.; Marbán, E.; Nakaya, H. Role of sarcolemmal KATP channels in cardioprotection against ischemia/reperfusion injury in mice. J. Clin. Invest, 2002, 109, 509-516. (Pubitemid 34171782)
97. Gumina, R.J.; Pucar, D.; Bast, P.; Hodgson, D.M.; Kurtz, C.E.; Dzeja, P.P.; Miki, T; Seino, S.; Terzic, A. Knockout of Kir6.2 negates ischemic preconditioning-induced protection of myocardial energetics. Am. J. Physiol, 2003, 284, H2106-H2113. (Pubitemid 36622422)
98. Gumina, R.J.; O'Cochlain, D.F.; Kurtz, C.E.; Bast, P.; Pucar, D.; Mishra, P.; Miki, T.; Seino, S.; Macura, S.; Terzic, A. K(ATP) channel knockout worsens myocardial calcium stress load in vivo and impairs recovery in stunned heart. Am. J. Physiol, 2007, 292, H1706-H1713. (Pubitemid 46572392)
99. Jovanovic, N; Jovanovic, S.; Jovanovic, A.; Terzic, A. Gene delivery of Kir6.2/SUR2A in conjunction with pinacidil handles intracellular Ca2+ homeostasis under metabolic stress. FASEB J., 1999, 13, 923-929. (Pubitemid 29220704)
100. Niho, T.; Notsu, T.; Ishikawa, H.; Funato, H.; Yamazaki, M.; Takahashi, H.; Tanaka, I.; Kayamoto, M.; Dabasaki, T.; Yamasaki, F.; Shinkawa, T.; Uemura, A.; Mizota, M. Study of mechanism and effect of sodium 5-hydroxydecanoate on experimental ischemic ventricular arrhythmia. Nippon Yakurigaku Zasshi. Folia Pharmacol. Japon., 1987, 89, 155-167. (Pubitemid 17021260)
101. Friedrichs, G.S.; Abreu, J.N; Black, S.C.; Chi, L.; Lucchesi, B.R. 5-hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death. Eur. J. Pharmacol, 1996, 306, 99-106. (Pubitemid 26200130)
102. Das, B.; Sarkar, C. Is the sarcolemmal or mitochondrial K(ATP) channel activation important in the antiarrhythmic and cardioprotective effects during acute ischemia/reperfusion in the intact anesthetized rabbit model? Life Sci., 2005, 77, 1226-1248. (Pubitemid 40898322)
103. Kita, H.; Miura, T.; Tsuchida, A.; Hasegawa, T.; Shimamoto, K. Suppression of reperfusion arrhythmias by preconditioning is inhibited by an ATP-sensitive potassium channel blocker, 5-hydroxydecanoate, but not by protein kinase C blockers in the rat. J. Cardiovasc. Pharmacol, 1998, 32, 791-797. (Pubitemid 28506651)
104. Kléber, A.G. Resting membrane potential, extracellular potassium activity, and intracellular sodium activity during acute global ischemia in isolated perfused guinea pig hearts. Circ. Res., 1983, 52, 442-450. (Pubitemid 13091202)
105. 2+ overload in cardiac myocytes via modulation of the diastolic membrane potential. Br. J. Pharmacol, 2004, 141, 1059-1067. (Pubitemid 38510090)
106. 2+ overload and depressed recovery of ventricular function of reperfused ischaemic rat hearts. Possible involvement of H(+)-Na(+) and Na(+)-Ca(2+) exchange. Circ. Res., 1989, 65, 1045-1056.
107. Murphy, E.; Perlman, M.; London, R.E.; Steenbergen, C. Amiloride delays the ischemia-induced rise in cytosolic calcium. Circ. Res., 1991, 68, 1250-1258.
108. Karmazyn, M. The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Ann. N Y Acad. Sci., 1999, 874, 326-334. (Pubitemid 29351954)
109. Schäfer, C.; Ladilov, Y; Inserte, J.; Schäfer, M.; Haffner, S.; Garcia-Dorado, D.; Piper, H.M. Role of the reverse mode of the Na+/Ca2+ exchanger in re-oxygenation-induced cardiomyocyte injury. Cardiovasc. Res., 2001, 51, 241-250. (Pubitemid 32695534)
110. Baczkó, I.; Giles, W.R.; Light, P.E. Resting membrane potential regulates Na+/Ca2+ exchange-mediated Ca2+ overload during hypoxia/reoxygenation in rat ventricular myocytes. J. Physiol, 2003, 550, 889-898. (Pubitemid 37010071)
111. Baczkó, I.; Jones, L.; McGuigan, C.F; Manning Fox, J.E.; Gandhi, M.; Giles, W.R.; Clanachan, A.S.; Light, P.E. Plasma-membrane KATP channel-mediated cardioprotection involves post-hypoxic reductions in calcium overload and contractile dysfunction: mechanistic insights into cardioplegia. FASEB J., 2005, 19, 980-982. (Pubitemid 40827724)
112. Antzelevitch C; Fish J. Electrical heterogeneity within the ventricular wall. Basic Res. Cardiol, 2001, 96, 517-527. (Pubitemid 33121024)
113. Janse, M.J.; Wit, A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol. Rev., 1989, 69, 1049-1169. (Pubitemid 19255835)
114. Furukawa, T; Kimura, S.; Furukawa, N; Bassett, A.L.; Myerburg, R.J. Role of cardiac ATP-regulated potassium channels in differential responses of endocardial and epicardial cells to ischemia. Circ. Res., 1991, 68, 1693-1702.
115. Di Diego, J.M.; Antzelevitch, C. Pinacidil-induced electrical heterogeneity and extrasystolic activity in canine ventricular tissues. Does activation of ATP-regulated potassium current promote phase 2 reentry. Circulation, 1993, 88, 1177-1189. (Pubitemid 23264037)
116. Robert, E.; Aya, A.G.; de la Coussaye, J.E.; Péray, P.; Juan, J.M.; Brugada, J.; Davy, J.M.; Eledjam, J.J. Dispersion-based reentry: mechanism of initiation of ventricular tachycardia in isolated rabbit hearts. Am. J. Physiol. 1999, 276, H413-H423. (Pubitemid 29100607)
117. Wolk, R.; Cobbe, S.M.; Kane, K.A.; Hicks, M.N. Relevance of inter- and intraventricular electrical dispersion to arrhythmogenesis in normal and ischaemic rabbit myocardium: a study with cromakalim, 5-hydroxydecanoate and glibenclamide. J. Cardiovasc. Pharmacol, 1999, 33, 323-334. (Pubitemid 29066677)
118. Krumenacker, M.; Roland, E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. J. Cardiovasc. Pharmacol, 1992, 20 Suppl. 3, S93-S102.
119. Simpson, D.; Wellington, K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs, 2004, 64, 1941-1955. (Pubitemid 39263662)
120. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet, 2002, 359, 1269-1275.
121. Wilde, A.A.; Escande, D.; Schumacher, C.A.; Thuringer, D.; Mestre, M.; Fiolet, J.W.; Janse, M.J. Potassium accumulation in the globally ischemic mammalian heart. A role for the ATP-sensitive potassium channel. Circ. Res., 1990, 67, 835-843. (Pubitemid 20315015)
122. Smallwood, J.K.; Ertel, P.J.; Steinberg, M.I. Modification by glibenclamide of the electrophysiological consequences of myocardial ischaemia in dogs and rabbits. Naunyn Schmiedebergs Arch. Pharmacol., 1990, 342, 214-220. (Pubitemid 20258842)
123. Hamada, K.; Yamazaki, J.; Nagao, T. Shortening of monophasic action potential duration during hyperkalemia and myocardial ischemia in anesthetized dogs. Jpn. J. Pharmacol., 1998, 76, 149-154. (Pubitemid 28140407)
124. Pogátsa, G.; Koltai, M.Z.; Balkányi, I.; Dévai, I.; Kiss, V.; Köszeghy, A. The effect of various hypoglycaemic sulphonylureas on the cardiotoxicity of glycosides and arrhythmogenic activity due to myocardial ischaemia. Acta Physiol. Hung., 1988, 71, 243-250.
125. Bril, A.; Laville, M.P.; Gout, B. Effects of glibenclamide on ventricular arrhythmias and cardiac function in ischaemia and reperfusion in isolated rat heart. Cardiovasc. Res., 1992, 26, 1069-1076.
126. + loss in a model of ischaemia in perfused guinea-pig hearts in vitro. Eur. J. Pharmacol., 1992, 220, 231-236.
127. Tosaki, A.; Engelman, D.T.; Engelman, R.M.; Das, D.K. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. J. Pharmacol. Exp. Ther., 1995, 275, 1115-1123. (Pubitemid 26129912)
128. Koltai, M.Z. Influence of hypoglycaemic sulphonylureas on the electro-physiological parameters of the heart. Diabetes Res. Clin. Pract., 1996, 31 Suppl, S15-S20. (Pubitemid 26258875)
129. Barrett, T.D.; Walker, M.J. Glibenclamide does not prevent action potential shortening induced by ischemia in anesthetized rabbits but reduces ischemiainduced arrhythmias. J. Mol. Cell. Cardiol., 1998, 30, 999-1008. (Pubitemid 28279312)
130. Zhu, B.M.; Miyamoto, S.; Nagasawa, Y.; Wajima, T.; Hashimoto, K. Effect of the sarcolemmal K(ATP) channel blocker HMR1098 on arrhythmias induced by programmed electrical stimulation in canine old myocardial infarction model: comparison with glibenclamide. J. Pharmacol. Sci., 2003, 93, 106-113. (Pubitemid 37254274)
131. Tomaselli, G.F.; Zipes, D.P. What causes sudden death in heart failure? Circ. Res., 2004, 95, 754-763. (Pubitemid 39390577)
132. Vermeulen, J.T.; McGuire, M.A.; Opthof, T.; Coronel, R.; de Bakker, J.M.; Klöpping, C.; Janse, M.J. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc. Res., 1994, 28, 1547-1554. (Pubitemid 24318270)
133. Keung, E.C.; Aronson, R.S. Non-uniform electrophysiologic properties and electrotonic interaction in hypertrophied rat myocardium. Circ. Res., 1981, 49, 150-158. (Pubitemid 11093190)
134. Bryant, S.M.; Shipsey, S.J.; Hart, G. Regional differences in electrical and mechanical properties of myocytes from guinea-pig hearts with mild left ventricular hypertrophy. Cardiovasc. Res., 1997, 35, 315-323. (Pubitemid 27372043)
135. Pak, P.H.; Nuss, H.B.; Tunin, R.S.; Kääb, S.; Tomaselli, G.F.; Marban, E.; Kass, D.A. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J. Am. Coll. Cardiol., 1997, 30, 576-584. (Pubitemid 27339341)
136. Yan, G.X.; Rials, S.J.; Wu, Y.; Liu, T.; Xu, X.; Marinchak, R.A.; Kowey, P.R. Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. Am. J. Physiol., 2001, 281, H1968- H1975.
137. Akar, F.G.; Yan, G.X.; Antzelevitch, C.; Rosenbaum, D.S. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation, 2002, 105, 1247-1253. (Pubitemid 34225828)
138. Nissen, J.D.; Diness, J.G.; Diness, T.G.; Hansen, R.S.; Grunnet, M.; Jespersen, T. Pharmacologically Induced Long QT Type 2 Can Be Rescued by Activation of IKs With Benzodiazepine R-L3 in Isolated Guinea Pig Cardiomyocytes. J. Cardiovasc. Pharmacol., 2009, 54, 169-177.
139. Magyar, J.; Horváth, B.; Bányász, T.; Szentandrássy, N.; Birinyi, P.; Varró, A.; Szakonyi, Z.; Fülöp, F.; Nánási, P. P. L-364,373 fails to activate the slow delayed rectifier K+ current in canine ventricular cardiomyocytes. Naunyn Schmiedebergs Arch. Pharmacol., 2006, 373, 85-89.
140. Veldkamp, M.W.; van Ginneken, A.C.; Opthof, T.; Bouman, L.N. Delayed rectifier channels in human ventricular myocytes. Circulation, 1995, 92, 3497-3504.
141. Volders, P.G.; Sipido, K.R.; Vos, M.A.; Spatjens, R.L.H.M.G.; Leunissen, J.D.M.; Carmeliet, E.; Wellens, H.J. Downregulation of delayed rectifier K+ currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation, 1999, 100, 2455-2461.
142. Tsuji, Y.; Opthof, T.; Kamiya, K.; Yasui, K.; Liu, W.; Lu, Z.; Kodama, I. Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle. Cardiovasc. Res., 2000, 48, 300-309.
143. Li, G.R.; Lau, C.P.; Ducharme, A.; Tardif, J.C.; Nattel, S. Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. Am. J. Physiol. Heart Circ. Physiol., 2002, 283, H1031-H1041.
144. Janse, M.J.; van Capelle, F.J.; Morsink, H.; Kléber, A.G.; Wilms-Schopman, F.; Cardinal, R.; d'Alnoncourt, C.N.; Durrer, D. Flow of "injury" current and patterns of excitation during early ventricular arrhythmias in acute regional myocardial ischemia in isolated porcine and canine hearts. Evidence for two different arrhythmogenic mechanisms. Circ. Res., 1980, 47, 151-165. (Pubitemid 10056042)
145. Fei, H.; Frame, L.H. D-Sotalol terminates reentry by two mechanisms with different dependence on the duration of the excitable gap. J. Pharmacol. Exp. Ther., 1996, 277, 174-185. (Pubitemid 27169058)
146. Patterson, E.; Scherlag, B.J.; Lazzara, R. Early afterdepolarizations produced by d,l-sotalol and clofilium. J. Cardiovasc. Electrophysiol., 1997, 8, 667-678. (Pubitemid 27265863)
147. Antzelevitch, C.; Di Diego, J.M. Role of K+ channel activators in cardiac electrophysiology and arrhythmias. Circulation, 1992, 85, 1627-1629.
148. Haverkamp, W.; Borggrefe, M.; Breithardt, G. Electrophysiologic effects of potassium channel openers. Cardiovasc. Drugs Ther., 1995, 9, 195-202.
149. Horinaka, S.; Kobayashi, N.; Yabe, A.; Asakawa, H.; Yagi, H.; Mori, Y.; Tsubokou, Y.; Yoshida, K.; Nakano, S.; Matsuoka, H. Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction. Cardiovasc. Drugs Ther., 2004, 18, 13-22. (Pubitemid 38992594)
150. Yang, Z.; Shi, G.; Li, C.; Wang, H.; Liu, K.; Liu,Y. Electrophysiologic effects of nicorandil on the guinea pig long QT1 syndrome model. J. Cardiovasc. Electrophysiol., 2004, 15, 815-820. (Pubitemid 38951857)
151. Sato, T.; Hata, Y.; Yamamoto, M.; Morita, H.; Mizuo, K.; Yamanari, H.; Saito, D.; Ohe, T. Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome. J. Cardiovasc. Electrophysiol., 1995, 6, 279-282.
152. Shimizu, W.; Kurita, T.; Matsuo, K.; Suyama, K.; Aihara, N.; Kamakura, S.; Towbin, J.A.; Shimomura, K. Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long-QT syndrome. Circulation, 1998, 97, 1581-1588. (Pubitemid 28186186)
153. Uchida, T.; Yashima, M.; Gotoh, M.; Qu, Z.; Garfinkel, A.; Weiss, J.N.; Fishbein, M.C.; Mandel, W.J., Chen, P.S.; Karagueuzian, H.S. Mechanism of acceleration of functional reentry in the ventricle: effects of ATP-sensitive potassium channel opener. Circulation, 1999, 99, 704-712. (Pubitemid 29077371)
154. Testai, L.; Cecchetti, V.; Sabatini, S.; Martelli, A.; Breschi, M.C.; Calderone, V. Effects of K(ATP) openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs. J. Pharm. Pharmacol., 2010, 62, 924-930.
155. Harris, AS. Potassium and experimental coronary occlusion. Am. Heart J., 1966, 71, 797-802.
156. + activity in swine. Circulation, 1980, 61, 768-778. (Pubitemid 10133894)
157. Johnson, T.A.; Engle, C.L.; Boyd, L.M.; Koch, G.G.; Gwinn, M.; Gettes, L.S. Magnitude and time course of extracellular potassium inhomogeneities during acute ischemia in pigs. Effect of verapamil. Circulation, 1991, 83, 622-634.
158. Wilde, A.A. ATP and the role of IK. ATP during acute myocardial ischemia: controversies revive. Cardiovasc. Res., 1997, 35, 181-183. (Pubitemid 27372028)
159. Hicks, M.N.; Cobbe, S.M. Effect of glibenclamide on extracellular potassium accumulation and the electrophysiological changes during myocardial ischaemia in the arterially perfused interventricular septum of rabbit. Cardiovasc. Res., 1991, 25, 407-413.
160. Kanda, A.; Watanabe, I.; Williams, M.L.; Engle, C.L.; Li, S.; Koch, G.G.; Gettes, L.S. Unanticipated lessening of the rise in extracellular potassium during ischemia by pinacidil. Circulation, 1997, 95, 1937-1944. (Pubitemid 27164413)
161. Venkatesh, N.; Stuart, J.S.; Lamp, S.T.; Alexander, L.D.; Weiss, J.N. Activation of ATP-sensitive K+ channels by cromakalim. Effects on cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle. Circ. Res., 1992, 71, 1324-1333.
162. Saito, T.; Sato, T.; Miki, T.; Seino, S.; Nakaya, H. Role of ATP-sensitive K+ channels in electrophysiological alterations during myocardial ischemia: a study using Kir6.2-null mice. Am. J. Physiol., 2005, 288, H352-H357. (Pubitemid 40023866)
163. Mitani, A.; Shattock, M.J. Role of Na-activated K channel, Na-K-Cl cotransport, and Na-K pump in [K]e changes during ischemia in rat heart. Am. J. Physiol., 1992, 263, H333-H340.
164. Shieh, R.C.; Goldhaber, J.I.; Stuart, J.S.; Weiss, J.N. Lactate transport in mammalian ventricle. General properties and relation to K+ fluxes. Circ. Res., 1994, 74, 829-838.
165. Yan, G.X.; Yamada, K.A.; Kléber, A.G.; McHowat, J.; Corr, P.B. Dissociation between cellular K+ loss, reduction in repolarization time, and tissue ATP levels during myocardial hypoxia and ischemia. Circ. Res., 1993, 72, 560-570. (Pubitemid 23052154)
166. Wang, J.; Wang, H.; Han, H.; Zhang, Y.; Yang, B.; Nattel, S.; Wang, Z. Phospholipid metabolite 1-palmitoyl-lysophosphatidylcholine enhances human ether-a-go-go-related gene (HERG) K(+) channel function. Circulation, 2001, 104, 2645-2648. (Pubitemid 33108127)
167. Yan, G.X.; Chen, J.; Yamada, K.A.; Kléber, A.G.; Corr, P.B. Contribution of shrinkage of extracellular space to extracellular K+ accumulation in myocar-dial ischaemia of the rabbit. J. Physiol., 1996, 490, 215-228. (Pubitemid 26020141)
168. Sasaki, N.; Sato, T.; Marban, E.; O'Rourke, B. ATP consumption by uncoupled mitochondria activates sarcolemmal K(ATP) channels in cardiac myocytes. Am. J. Physiol., 2001, 280, H1882-H1888.
169. Gao, S.; Long, C.L.; Wang, R.H.; Wang, H. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc. Res., 2009, 83, 444-456.
170. Haïssaguerre, M.; Chatel, S.; Sacher, F.; Weerasooriya, R.; Probst, V.; Loussouarn, G.; Horlitz, M.; Liersch, R.; Schulze-Bahr, E.; Wilde, A.; Kääb, S.; Koster, J.; Rudy, Y.; Le Marec, H.; Schott, J.J. Ventricular fibrillation with prominent early repolarization associated with a rare variant of KCNJ8/K(ATP) channel. J. Cardiovasc. Electrophysiol., 2009, 20, 93-98.
171. Medeiros-Domingo, A.; Tan, B.H.; Crotti, L.; Tester, D.J.; Eckhardt, L.; Cuoretti, A.; Kroboth, S.L.; Song, C.; Zhou, Q.; Kopp, D.; Schwartz, P.J.; Makielski, J.C.; Ackerman, M.J. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm., 2010, 7, 1466-1471.
172. Glukhov, A.V.; Flagg, T.P.; Fedorov, V.V.; Efimov, I.R.; Nichols, C.G. Differential K(ATP) channel pharmacology in intact mouse heart. J. Mol. Cell. Cardiol., 2010, 48, 152-160.
173. + current density during chronic human atrial fibrillation. J. Mol. Cell. Cardiol., 2003, 35, 1399-1405. (Pubitemid 37491183)
174. + channels. J. Am. Coll. Cardiol., 2001, 37, 926-932. (Pubitemid 32202465)
175. Vereckei, A.; Gögelein, H.; Wirth, K.J.; Zipes, D.P. Effect of the cardioselective, sarcolemmal KATP channel blocker HMR 1098 on atrial electrical remodeling during pacing-induced atrial fibrillation in dogs. Cardiovasc. Drugs Ther., 2004, 18, 23-30. (Pubitemid 38992595)
176. Jahangir, A.; Terzic, A. K(ATP) channel therapeutics at the bedside. J. Mol. Cell. Cardiol., 2005, 39, 99-112.
177. Mannhold, R. KATP channel openers: structure-activity relationships and therapeutic potential. Med. Res. Rev., 2004, 24, 213-266. (Pubitemid 38230680)
178. Mannhold, R. Structure-activity relationships of K(ATP) channel openers. Curr. Top. Med. Chem., 2006, 6, 1031-1047. (Pubitemid 43796964)
179. Hansen, J.B. Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr. Med. Chem., 2006, 13, 361-376.
180. Rubin, A.A.; Roth, F.E.; Winbury, M.M. A non-diuretic benzothiadiazine with anti-hypertensive properties. Nature, 1961, 192, 176-177.
181. Hutcheon, D.E.; Barthalmus, K.S. Antihypertensive action of diazoxide. A new benzothiazine with antidiuretic properties. B r. Med. J., 1962, 2, 159-161.
182. Dunne, M.J.; Kane, C.; Shepherd, R.M.; Sanchez, J.A.; James, R.F.; Johnson, P.R.; Aynsley-Green, A.; Lu, S; Clement, J.P.4th.; Lindley, K.J.; Seino, S.; Aguilar-Bryan, L. Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N. Engl. J. Med., 1997, 336, 703-706. (Pubitemid 27102685)
183. Parker, J.J.; Allen, D.B. Hypertrophic cardiomyopathy after prolonged dia-zoxide therapy for hyperinsulinemic hypoglycemia. J. Pediatr., 1991, 118, 906-909.
184. Varon, J.; Marik, P.E. The diagnosis and management of hypertensive crises. Chest, 2000, 118, 214-227. (Pubitemid 30485512)
185. Thien, T.A.; Huysmans, F.T.; Gerlag, P.G., Koene, R.A.; Wijdeveld, P.G. Diazoxide infusion in severe hypertension and hypertensive crisis. Clin. Pharmacol. Ther., 1979, 25, 795-799. (Pubitemid 10192739)
186. Klinke, W.P.; Gilbert, J.A. Diazoxide in primary pulmonary hypertension. N. Engl. J. Med., 1980, 302, 91-92. (Pubitemid 10210624)
187. Liu, Y.; Sato, T.; Seharaseyon, J.; Szewczyk, A.; O'Rourke, B.; Marbán, E. Mitochondrial ATP-dependent potassium channels. Viable candidate effectors of ischemic preconditioning. Ann. N. Y. Acad. Sci. 1999, 874, 27-37. (Pubitemid 29351928)
188. Matejíková, J.; Ravingerová, T.; Pancza, D.; Carnická, S.; Kolár, F. Mitochondrial KATP opening confers protection against lethal myocardial injury and ischaemia-induced arrhythmias in the rat heart via PI3K/Akt-dependent and -independent mechanisms. Can. J. Physiol. Pharmacol., 2009, 87, 1055-1062.
189. Mull, K.P.; Debnam, Q.; Kabir, S.M.; Bhattacharyya, M.L. Role of action potential shortening in the prevention of arrhythmias in canine cardiac tissue. Clin. Exp. Pharmacol. Physiol., 1999, 26, 964-969. (Pubitemid 30004317)
190. Petersen, H.J.; Nielsen, C.K.; Arrigoni-Martelli, E. Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines. J. Med. Chem., 1978, 21, 773-781.
191. Standen, N.B.; Quayle, J.M.; Davies, N.W.; Brayden, J.E.; Huang, Y.; Nelson, M.T. Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science, 1989, 245, 177-180. (Pubitemid 19193933)
192. McCarron, J.G.; Quayle, J.M.; Halpern, W.; Nelson, M.T. Cromakalim and pinacidil dilate small mesenteric arteries but not small cerebral arteries. Am. J. Physiol., 1991, 261, H287-H291.
193. D'Alonzo, A.J.; Hess, T.A.; Darbenzio, R.B.; Sewter, J.C. Effects of intra-coronary cromakalim, pinacidil, or diltiazem on cesium chloride-induced arrhythmias in anesthetized dogs under conditions of controlled coronary blood flow. J. Cardiovasc. Pharmacol., 1993, 21, 677-683. (Pubitemid 23095361)
194. Fish, F.A.; Prakash, C.; Roden, D.M. Suppression of repolarization- related arrhythmias in vitro and in vivo by low-dose potassium channel activators. Circulation, 1990, 82, 1362-1369.
195. D'Alonzo, A.J.; Hess, T.A.; Darbenzio, R.B.; Sewter, J.C.; Conder, M.L.; McCullough, J.R. Effects of cromakalim or pinacidil on pacing- and ischemia-induced ventricular fibrillation in the anesthetized pig. Basic Res. Cardiol., 1994, 89, 163-176. (Pubitemid 24208804)
196. Fischbach, P.S.; White, A.; Barrett, T.D.; Lucchesi, B.R. Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel. J. Pharmacol. Exp. Ther., 2004, 309, 554-559. (Pubitemid 38542607)
197. Black, S.C.; Lucchesi, B.R. Potassium channel openers are likely to be proarrhythmic in the diseased human heart. Cardiovasc. Res., 1994, 28, 923-924. (Pubitemid 24221610)
198. Buckingham, R.E.; Clapham, J.C.; Hamilton, T.C.; Longman, S.D.; Norton, J.; Poyser, R.H. BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J. Cardiovasc. Pharmacol., 1986, 8, 798-804. (Pubitemid 16061317)
199. Cook, N.S.; Hof, R.P. Cardiovascular effects of apamin and BRL 34915 in rats and rabbits. B r. J. Pharmacol., 1988, 93, 121-131.
200. Donnelly, R.; Elliott, H.L.; Meredith, P.A.; Reid, J.L. Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects. J. Cardiovasc. Pharmacol., 1990, 16, 790-795. (Pubitemid 20345263)
201. Hof, R.P.; Quast, U.; Cook, N.S.; Blarer, S. Mechanism of action and systemic and regional hemodynamics of the potassium channel activator BRL34915 and its enantiomers. Circ. Res., 1988, 62, 679-686.
202. Grover, G.J.; Dzwonczyk, S.; Parham, C.S.; Sleph, P.G. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc. Drugs Ther., 1990, 4: 465-474. (Pubitemid 20208398)
203. Sanada, S.; Kitakaze, M.; Asanuma, H.; Harada, K.; Ogita, H.; Node, K.; Takashima, S.; Sakata, Y.; Asakura, M.; Shinozaki, Y.; Mori, H.; Kuzuya, T.; Hori, M. Role of mitochondrial and sarcolemmal K(ATP) channels in ischemic preconditioning of the canine heart. Am. J. Physiol. Heart Circ. Physiol., 2001, 280, H256-H263.
204. Tsukamoto, O.; Asanuma, H.; Kim, J.; Minamino, T.; Takashima, S.; Ogai, A.; Hirata, A.; Fujita, M.; Shinozaki, Y.; Mori, H.; Tomoike, H.; Hori, M.; Kitakaze, M. A role of opening of mitochondrial ATP-sensitive potassium channels in the infarct size-limiting effect of ischemic preconditioning via activation of protein kinase C in the canine heart. Biochem. Biophys. Res. Commun., 2005, 338, 1460-1466. (Pubitemid 41608414)
205. Das, B.; Sarkar, C. Mitochondrial KATP channel activation is important in the antiarrhythmic and cardioprotective effects of non-hypotensive doses of nicorandil and cromakalim during ischemia/reperfusion: a study in an intact anesthetized rabbit model. Pharmacol. Res., 2003, 47, 447-461. (Pubitemid 36542923)
206. Coetzee, W.A.; Wells, T.; Avkiran, M. Anti-arrhythmic effects of levcro-makalim in the ischaemic rat heart: a dual mechanism of action? Eur. J. Pharmacol., 2000, 25, 402, 263-274. (Pubitemid 30665853)
207. Remme, C.A.; Schumacher, C.A.; de Jong, J.W.; Fiolet, J.W.; de Groot, J.R.; Coronel, R.; Wilde, A.A. K(ATP) channel opening during ischemia: effects on myocardial noradrenaline release and ventricular arrhythmias. J. Cardiovasc. Pharmacol., 2001, 38, 406-416. (Pubitemid 32769560)
208. Uchida, Y.; Yoshimoto, N.; Murao, S. Effect of 2-nicotinamidethyl nitrate (SG 75) on coronary circulation. Jpn. Heart J., 1978, 19, 112-124. (Pubitemid 8361109)
209. Itoh, T.; Furukawa, K.; Kajiwara, M.; Kitamura, K.; Suzuki, H.; Ito, Y.; Kuriyama, H. Effects of 2-nicotinamidoethyl nitrate on smooth muscle cells and on adrenergic transmission in the guinea-pig and porcine mesenteric arteries. J. Pharmacol. Exp. Ther., 1981, 218, 260-270. (Pubitemid 11033748)
210. Furukawa, K.; Itoh, T.; Kajiwara, M.; Kitamura, K.; Suzuki, H.; Ito, Y.; Kuriyama, H. Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea-pig coronary arteries. J. Pharmacol. Exp. Ther., 1981, 218, 248-259. (Pubitemid 11033747)
211. Mizumura, T.; Saito, S.; Ozawa, Y.; Kanmatsuse, K.; Gross, G.J. An ATP-sensitive potassium (KATP) channel opener, nicorandil, lowers the threshold for ischemic preconditioning in barbital-anesthetized dogs. Heart Vessels., 1997, Suppl 12, 175-177.
212. Imagawa, J.; Baxter, G.F.; Yellon, D.M. Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J. Cardiovasc. Pharmacol., 1998, 31, 74-79. (Pubitemid 28027901)
213. Steensrud, T.; Nordhaug, D.; Husnes, K.V.; Aghajani, E.; Sørlie, D.G. Replacing potassium with nicorandil in cold St. Thomas' Hospital cardioplegia improves preservation of energetics and function in pig hearts. Ann. Thorac. Surg., 2004, 77, 1391-1397. (Pubitemid 38452385)
214. Holzmann, S. Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75). J. Cardiovasc. Pharmacol., 1983, 5, 364-370. (Pubitemid 13080752)
215. Biermann, J.; Wu, K.; Odening, K.E.; Asbach, S.; Koren, G.; Peng, X.; Zehender, M.; Bode, C.; Brunner, M. Nicorandil normalizes prolonged repolarisation in the first transgenic rabbit model with Long-QT syndrome 1 both in vitro and in vivo. Eur. J. Pharmacol., 2011, 650, 309-316.
216. Iida, S.; Kinoshita, H.; Holford, N.H. Population pharmacokinetic and phar-macodynamic modelling of the effects of nicorandil in the treatment of acute heart failure. B r. J. Clin. Pharmacol., 2008, 66, 352-365.
217. Patel, D.J.; Purcell, H.J.; Fox, K.M. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. Eur. Heart J., 1999, 20, 51-57. (Pubitemid 29027526)
218. Kato, T.; Kamiyama, T.; Maruyama, Y.; Tanaka, S.; Yoshimoto, N. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. Am. Heart J., 2001, 141, 940-943. (Pubitemid 32477005)
219. Ota, S.; Nishikawa, H.; Takeuchi, M.; Nakajima, K.; Nakamura, T.; Okamoto, S.; Setsuda, M.; Makino, K.; Yamakado, T.; Nakano, T. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ. J., 2006, 70, 1099-1104. (Pubitemid 44386986)
220. Sica, D.A. Minoxidil: an underused vasodilator for resistant or severe hypertension. J. Clin. Hypertens. (Greenwich), 2004, 6, 283-287.
221. Rumsfield, J.A.; West, D.P.; Fiedler-Weiss, V.C. Topical minoxidil therapy for hair regrowth. Clin. Pharm., 1987, 6, 386-392. (Pubitemid 17082966)
222. Franciosa, J.A.; Jordan, R.A.; Wilen, M.M.; Leddy, C.L. Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation, 1984, 70, 63-68. (Pubitemid 14084067)
223. Das, B.; Sarkar, C; Karanth, K.S. Selective mitochondrial K(ATP) channel activation results in antiarrhythmic effect during experimental myocardial ischemia/reperfusion in anesthetized rabbits. Eur. J. Pharmacol, 2002, 437, 165-171. (Pubitemid 34219478)
224. Sato, T.; Sasaki, N; Seharaseyon, J.; O'Rourke, B.; Marbán, E. Selective pharmacological agents implicate mitochondrial but not sarcolemmal K(ATP) channels in ischemic cardioprotection. Circulation, 2000, 101, 2418-2423. (Pubitemid 30329134)
225. Nygren, A.; Baczkó, I.; Giles, W.R. Measurements of electrophysiological effects of components of acute ischemia in Langendorff-perfused rat hearts using voltage-sensitive dye mapping. J. Cardiovasc. Electrophysiol., 2006, 17 Suppl 1, S113-S123.
226. Smallwood, J.K.; Steinberg, M.I. Cardiac electrophysiological effects of pinacidil and related pyridylcyanoguanidines: relationship to antihypertensive activity. J. Cardiovasc. Pharmacol, 1988, 12, 102-129.
227. Sargent, CA.; Sleph, P.G.; Dzwonczyk, S.; Normandin, D.; Antonaccio, M.J.; Grover, G.J. Cardioprotective effects of the cyanoguanidine potassium channel opener P-1075. J. Cardiovasc. Pharmacol, 1993, 22, 564-570. (Pubitemid 23286752)
228. Jilkina, O.; Kuzio, B.; Grover, G.J.; Kupriyanov, V.V. Cardioselective sul-fonylthiourea HMR 1098 blocks mitochondrial uncoupling induced by a KATP channel opener, P-1075, in beating rat hearts. Biochim. Biophys. Acta, 2003, 1638, 121-128. (Pubitemid 36829269)
229. Sato, T; Nakaya, H. P-1075 exerts diverse modulatory effects on mitochondrial ATP-sensitive K+ channels in rabbit ventricular myocytes. J. Cardiovasc. Pharmacol, 2006, 47, 165-168. (Pubitemid 44384052)
230. Daut. J.; Klieber, H.G.; Cyrys, S.; Noack, T. KATP channels and basal coronary vascular tone. Cardiovasc. Res., 1994, 28, 811-817.
231. Rovnyak, G.C; Ahmed, S.Z.; Ding, C.Z.; Dzwonczyk, S.; Ferrara, FN.; Humphreys, W.G.; Grover, G.J.; Santafianos, D.; Atwal, K.S.; Baird, A.J.; McLaughlin, L.G.; Normandin, D.E.; Sleph, P.G.; Traeger, S.C Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity J. Med. Chem., 1997, 40, 24-34. (Pubitemid 27027262)
232. Ding, C.Z.; Rovnyak, G.C; Misra, R.N.; Grover, G.J.; Miller, A.V.; Ahmed, S.Z.; Kelly, Y.; Normandin, D.E.; Sleph, P.G.; Atwal, K.S. Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines. J. Med. Chem., 1999, 42, 3711-3717. (Pubitemid 29445104)
233. Grover, G.J.; Atwal, K.S. Pharmacologic profile of the selective mitochon-drial-K(ATP) opener BMS-191095 for treatment of acute myocardial ischemia. Cardiovasc. Drug Rev., 2002, 20, 121-136.
234. Cho, M.R.; Park, J.W.; Jung, IS.; Yi, K.Y; Yoo, S.E.; Chung, H.J.; Yun, Y.P.; Kwon, S.H.; Shin, H.S. BMS-191095, a cardioselective mitochondrial K(ATP) opener, inhibits human platelet aggregation by opening mitochondrial K(ATP) channels. Arch. Pharm. Res., 2005, 28, 61-67.
235. Lee, S.H.; Yang, M.K.; Lim, J.H.; Seo, H.W.; Yi, K.Y; Yoo, S.E.; Lee, B.H.; Won, H.S.; Lee, CS.; Choi, W.S.; Shin, H.S. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury. Arch. Pharm. Res., 2008, 31, 482-489.
236. Yang, M.K.; Lee, S.H.; Seo, H.W.; Yi, K.Y; Yoo, S.E.; Lee, B.H.; Chung, H.J.; Won, H.S.; Lee, CS.; Kwon, S.H.; Choi, W.S.; Shin, H.S. KR-31761, a novel K+ATP-channel opener, exerts cardioprotective effects by opening both mitochondrial K+ATP and Sarcolemmal K+ATP channels in rat models of ischemia/reperfusion-induced heart injury. J Pharmacol. Sci, 2009, 109, 222-232.
237. Sato, T.; Takizawa, T.; Saito, T.; Kobayashi, S.; Hara, Y; Nakaya, H. Amiodarone inhibits sarcolemmal but not mitochondrial KATP channels in Guinea pig ventricular cells. J. Pharmacol. Exp. Ther, 2003, 307, 955-960. (Pubitemid 37494212)
238. Kodama, I.; Kamiya, K.; Toyama, J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol. 1999, 84, 20R-28R.
239. Franke, H.; Fuchs, J. A new anti-diabetes principle; results of clinical research. Deut. Med. Wochschrift, 1955, 7, 1449-1452.
240. Fosset, M.; De Weille, J.R.; Green, R.D.; Schmid-Antomarchi, H.; Lazdunski, M. Antidiabetic sulfonylureas control action potential properties in heart cells via high affinity receptors that are linked to ATP-dependent K+ channels. J. Biol. Chem, 1988, 263, 7933-7936.
241. Englert, H.C.; Heitsch, H.; Gerlach, U.; Knieps, S. Blockers of the ATP-sensitive potassium channel SURA/Kir6.2: a new approach to prevent sudden cardiac death. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 2003, 1, 253-271.
242. Ballagi-Pordany, G.; Koszeghy, A.; Koltai, M.Z.; Aranyi, Z.; Pogatsa, G. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Res. Clin. Pract, 1990, 8, 109-114. (Pubitemid 20034058)
243. Csonka, C; Onody, A.; Csont, T.; Ferdinandy, P. Defibrillatory action of glibenclamide is independent from ATP-sensitive K+ channels and free radicals. J. Cardiovasc. Pharmacol, 2003, 41, 916-922. (Pubitemid 36706140)
244. Mocanu, M.M.; Maddock, H.L.; Baxter, G.F.; Lawrence, C.L.; Standen, N.B.; Yellon, D.M. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation, 2001, 103, 3111-3116. (Pubitemid 32587859)
245. Végh, A; Papp J.G. Haemodynamic and other effects of sulphonylurea drugs on the heart. Diabetes Res. Clin. Pract. 1996, 31 Suppl, S43-S53. (Pubitemid 26258879)
246. Negroni, JA.; Lascano, E.C.; del Valle, H.F. Glibenclamide action on myocardial function and arrhythmia incidence in the healthy and diabetic heart. Cardiovasc. Hematol. Agents Med. Chem., 2007, 5, 43-53. (Pubitemid 46062421)
247. Aronson, D.; Mittleman, M.A.; Burger, A.J. Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure. Pacing Clin. Electrophysiol, 2003, 26, 1254-1261. (Pubitemid 36570896)
248. Kecskeméti, V.; Bagi, Z.; Pacher, P.; Pósa, I.; Kocsis, E.; Koltai, M.Z. New trends in the development of oral antidiabetic drugs. Curr. Med. Chem., 2002, 9, 53-71. (Pubitemid 34436450)
249. Yamazaki, J.; Hume, J.R. Inhibitory effects of glibenclamide on cystic fibrosis transmembrane regulator, swelling-activated, and Ca(2+)-activated Cl(-) channels in mammalian cardiac myocytes. Circ. Res., 1997, 81, 101-109. (Pubitemid 27272988)
250. Schaffer, P; Pelzmann, B.; Bernhart, E.; Lang, P.; Machler, H.; Rigler, B.; Koidl, B. The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes. Br. J. Pharmacol, 1999, 128, 1175-1180.
251. Gögelein, H.; Hartung, J.; Englert, H.C.; Scholkens, BA. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part I: effects on cardiomyocytes, coronary flow and pancreatic beta-cells. J. Pharmacol. Exp. Ther, 1998; 286 1453-1464. (Pubitemid 29135562)
252. Duncker, D.J.; Van Zon, N.S.; Altman, J.D.; Pavek, T.J.; Bache, R.J. Role of K+ATP channels in coronary vasodilation during exercise. Circulation, 1993, 88, 1245-1253. (Pubitemid 23264045)
253. Ardehali, H.; O'Rourke, B. Mitochondrial K(ATP) channels in cell survival and death. J. Mol. Cell. Cardiol, 2005, 39, 7-16. (Pubitemid 40836042)
254. Jung, O.; Englert, H.C.; Jung, W.; Gögelein, H.; Schölkens, B.A.; Busch, A.E.; Linz, W. The K(ATP) channel blocker HMR 1883 does not abolish the benefit of ischemic preconditioning on myocardial infarct mass in anesthetized rabbits. Naunyn Schmiedebergs Arch. Pharmacol, 2000, 361, 445-451. (Pubitemid 30148883)
255. Englert, H.C.; Gerlach, U.; Gögelein, H.; Hartung, J.; Heitsch, H.; Mania, D.; Scheidler, S. Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J. Med. Chem., 2001, 44, 1085-1098. (Pubitemid 32852134)
256. Manning Fox, J.E.; Kanji, H.D.; French, R.J.; Light, P.E. Cardioselectivity of the sulphonylurea HMR 1098: studies on native and recombinant cardiac and pancreatic K(ATP) channels. Br. J. Pharmacol, 2002, 135, 480-488. (Pubitemid 34151181)
257. Kääb, S.; Zwermann, L.; Barth, A.; Hinterseer, M.; Englert, H.C.; Gögelein, H.; Näbauer, M. Selective block of sarcolemmal I(KATP) in human cardiomyocytes using HMR 1098. Cardiovasc. Drugs Ther, 2003, 17, 435-
258. Zhang, H.X.; Akrouh, A.; Kurata, H.T.; Remedi, M.S.; Lawton, J.S.; Nichols, CG. HMR 1098 is not an SUR isotype specific inhibitor of heterologous or sarcolemmal K(ATP) channels. J. Mol. Cell. Cardiol, 2011, 50, 552-560.
259. Gok, S.; Vural, K.; Sekuri, C; Onur, R.; Tezcan, A.; Izanli, A. Effects of the blockade of cardiac sarcolemmal ATP-sensitive potassium channels on arrhythmias and coronary flow in ischemia-reperfusion model in isolated rat hearts. Vascul Pharmacol, 2006, 44, 197-205. (Pubitemid 43351178)
260. Weyermann, A.; Vollert, H.; Busch, A.E.; Bleich, M.; Gögelein, H. Inhibitors of ATP-sensitive potassium channels in guinea pig isolated ischemic hearts. Naunyn Schmiedebergs Arch. Pharmacol, 2004, 369, 374-381. (Pubitemid 38553672)
261. Tanno, M.; Tsuchida, A.; Nozawa, Y; Matsumoto, T.; Hasegawa, T.; Miura, T.; Shimamoto, K. Roles of tyrosine kinase and protein kinase C in infarct size limitation by repetitive ischemic preconditioning in the rat. J. Cardiovasc. Pharmacol, 2000, 35, 345-352. (Pubitemid 30127179)
262. Tsuchida, A.; Miura, T; Tanno, M.; Sakamoto, J.; Miki, T; Kuno, A.; Matsumoto, T.; Ohnuma, Y; Ichikawa, Y; Shimamoto, K. Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemmal K(ATP) channels, and protein kinase C. J. Am. Coll. Cardiol. 2002, 40, 1523-1530. (Pubitemid 35192880)
263. Marinovic, J.; Ljubkovic, M.; Stadnicka, A.; Bosnjak, Z.J.; Bienengraeber, M. Role of sarcolemmal ATP-sensitive potassium channel in oxidative stress-induced apoptosis: mitochondrial connection. Am. J. Physiol. Heart Circ. Physiol, 2008, 294, H1317-H1325. (Pubitemid 351468730)
264. Gill, A.; Flaim, S.F.; Damiano, B.P; Sit, S.P; Brannan, M.D. Pharmacology of bepridil. Am. J. Cardiol. 1992, 69, 11D-16D.
265. Sato, T; Costa, A.D.; Saito, T.; Ogura, T.; Ishida, H.; Garlid, K.D.; Nakaya, H. Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J. Pharmacol. Exp. Ther, 2006, 316, 182-188. (Pubitemid 41832595)
266. Wang, J.C; Kiyosue, T; Kiriyama, K.; Arita, M. Bepridil differentially inhibits two delayed rectifier K+ currents, IKr and IKs, in guinea-pig ventricular myocytes. Br. J. Pharmacol, 1999, 128, 1733-1738. (Pubitemid 30011887)
267. Manouvrier, J.; Sagot, M.; Caron, C; Vaskmann, G.; Leroy, R.; Reade, R.; Ducloux, G. Nine cases of torsade de pointes with bepridil administration. Am. Heart J. 1986, 111, 1005-1007. (Pubitemid 16092975)
268. Yasuda, M.; Nakazato, Y.; Sasaki, A.; Kawano, Y.; Nakazato, K.; Tokano, T.; Daida, H. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ. J., 2006, 70, 662-666. (Pubitemid 43797774)
269. Bienengraeber, M.; Olson, T.M.; Selivanov, V.A.; Kathmann, E.C.; O'Cochlain, F.; Gao, F.; Karger, A.B.; Ballew, J.D.; Hodgson, D.M.; Zingman, L.V.; Pang, Y.P.; Alekseev, A.E.; Terzic, A. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat. Genet., 2004, 36, 382-387. (Pubitemid 38437261)
270. Brown, D.A.; Lynch, J.M.; Armstrong, C.J.; Caruso, N.M.; Ehlers, L.B.; Johnson, M.S., Moore, R.L. Susceptibility of the heart to ischaemia- reperfusion injury and exercise-induced cardioprotection are sex-dependent in the rat. J. Physiol., 2005, 564, 619-630. (Pubitemid 40585058)
271. Chicco, A.J.; Johnson, M.S.; Armstrong, C.J.; Lynch, J.M.; Gardner, R.T.; Fasen, G.S.; Gillenwater, C.P.; Moore, R.L. Sex-specific and exerciseacquired cardioprotection is abolished by sarcolemmal KATP channel blockade in the rat heart. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H2432-H2437. (Pubitemid 47084626)
272. Johnson, M.S.; Moore, R.L.; Brown, D.A. Sex differences in myocardial infarct size are abolished by sarcolemmal KATP channel blockade in rat. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H2644-H2647. (Pubitemid 43846096)
273. Edwards, A.G.; Rees, M.L.; Gioscia, R.A.; Zachman, D.K.; Lynch, J.M.; Browder, J.C.; Chicco, A.J.; Moore, R.L. PKC-permitted elevation of sar-colemmal KATP concentration may explain female-specific resistance to myocardial infarction. J. Physiol., 2009, 587, 5723-5737.
274. Schulman, D.; Latchman, D.S.; Yellon, D.M. Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2001, 281, H1630-H1636.
275. Bartling, B.; Friedrich, I.; Silber, R.E.; Simm, A. Ischemic preconditioning is not cardioprotective in senescent human myocardium. Ann. Thorac. Surg. 2003, 76, 105-111. (Pubitemid 36819725)
276. Jovanovic, S.; Jovanovic, A. Sarcolemmal KATP channels in ageing. Ageing Res. Rev., 2004, 3, 199-214.